首页> 外文期刊>microRNA Diagnostics and Therapeutics >Can miRNA Biomarkers Be Utilized to Improve the Evaluation and Management of Pancreatic Cystic Lesions?
【24h】

Can miRNA Biomarkers Be Utilized to Improve the Evaluation and Management of Pancreatic Cystic Lesions?

机译:是否可以使用miRNA生物标记物改善胰腺囊性病变的评估和管理?

获取原文
       

摘要

This article reviews the current strategies and challenges of diagnosing pancreatic cystic lesions, and presents an overview of molecular tools that are available to enhance diagnostic accuracy. Specifically, we highlight the emergence of microRNAs (miRNAs) as diagnostic markers. miRNA signatures have been reported for both solid tissue and biofluid specimens, including cyst fluid, collected from patients with solid and cystic pancreatic lesions. These miRNA signatures offer the opportunity to improve molecular characterization of pancreatic lesions, to help guide clinical management through early diagnosis and informed prognosis, and to provide novel therapeutic targets for pancreatic cancer.
机译:本文回顾了诊断胰腺囊性病变的当前策略和挑战,并概述了可用于提高诊断准确性的分子工具。具体来说,我们重点介绍了microRNA(miRNA)作为诊断标记物的出现。对于实体组织和囊性胰腺病变患者收集的实体组织和生物流体标本,包括囊液,都已报道了miRNA签名。这些miRNA签名提供了改善胰腺病变分子特征的机会,有助于通过早期诊断和知情预后指导临床治疗,并为胰腺癌提供新的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号